Long Non-coding RNA LOXL1-AS1 Facilitates Colorectal Cancer Progression via Regulating miR-1224-5p/miR-761/HK2 Axis

Guo, Tao; Peng, Shihao; Liu, Defeng; Li, Yangyang

doi:10.1007/s10528-022-10226-3

Cited by 3 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further studies have revealed that LOXL1-AS1 enhances the proliferation, migration, invasion and progression of CRC through sponge miR-708-5p regulating CD44-EGFR signal pathway [ 22 ]. Guo et al [ 23 ] found that knocking down LOXL1-AS1 inhibits the CRC cells proliferation, migration, invasion and glycolysis and induces apoptosis in vitro. Silencing LOXL1-AS1 can inhibit CRC tumor growth in vivo.…”

Section: Role Of Loxl1-as1 In Various Cancersmentioning

confidence: 99%

“…In the model of RB xenotransplantation, knocking down LOXL1-AS1 can also significantly inhibit tumor growth and promote tumor cell apoptosis, indicating that LOXL1-AS1 is expected to be the basis for clinical treatment of RB [ 68 ]. LOXL1-AS1 inhibition using shRNA reduce the motor ability of CRC cells and significantly prevent tumor growth in vivo [ 23 ]. As an emerging lncRNA, the research on LOXL1-AS1 is still in pre-clinical stage and more large sample and multicenter studies are needed.…”

Section: Role Of Loxl1-as1 In Various Cancersmentioning

confidence: 99%

See 1 more Smart Citation

Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors

Fu,

Ji,

Tang

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are transcripts that contain more than 200 nucleotides. Despite their inability to code proteins, multiple studies have identified their important role in human cancer through different mechanisms. LncRNA lysyl oxidase like 1 antisense RNA 1 (LOXL1-AS1), a newly discovered lncRNA located on human chromosome 15q24.1, has recently been shown to be involved in the occurrence and progression of various malignancies, such as colorectal cancer, gastric cancer, hepatocellular carcinoma, prostate cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, breast cancer, glioma, thymic carcinoma, pancreatic carcinoma. LOXL1-AS1 acts as competitive endogenous RNA (ceRNA) and via sponging various miRNAs, including miR-374b-5p, miR-21, miR-423-5p, miR-589-5p, miR-28-5p, miR-324-3p, miR-708-5p, miR-143-3p, miR-18b-5p, miR-761, miR-525-5p, miR-541-3p, miR-let-7a-5p, miR-3128, miR-3614-5p, miR-377-3p and miR-1224-5p to promote tumor cell proliferation, invasion, migration, apoptosis, cell cycle, and epithelial–mesenchymal transformation (EMT). In addition, LOXL1-AS1 is involved in the regulation of P13K/AKT and MAPK signaling pathways. This article reviews the current understanding of the biological function and clinical significance of LOXL1-AS1 in human cancers. These findings suggest that LOXL1-AS1 may be both a reliable biomarker and a potential therapeutic target for cancers.

show abstract

Section: Role Of Loxl1-as1 In Various Cancersmentioning

confidence: 99%

Section: Role Of Loxl1-as1 In Various Cancersmentioning

confidence: 99%